294 related articles for article (PubMed ID: 19092244)
1. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
Mangel AW; Chaturvedi P
Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
[TBL] [Abstract][Full Text] [Related]
2. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.
Nee J; Salley K; Ludwig AG; Sommers T; Ballou S; Takazawa E; Duehren S; Singh P; Iturrino J; Katon J; Lee HN; Rangan V; Lembo AJ
Clin Transl Gastroenterol; 2019 Dec; 10(12):e00110. PubMed ID: 31800542
[TBL] [Abstract][Full Text] [Related]
3. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
Macarthur RD; Hawkins TN; Brown SJ; Lamarca A; Clay PG; Barrett AC; Bortey E; Paterson C; Golden PL; Forbes WP
HIV Clin Trials; 2013; 14(6):261-73. PubMed ID: 24334179
[TBL] [Abstract][Full Text] [Related]
5. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
[TBL] [Abstract][Full Text] [Related]
7. Crofelemer, a novel agent for treatment of secretory diarrhea.
Crutchley RD; Miller J; Garey KW
Ann Pharmacother; 2010 May; 44(5):878-84. PubMed ID: 20388859
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
9. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
10. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW
Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974
[TBL] [Abstract][Full Text] [Related]
14. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
[TBL] [Abstract][Full Text] [Related]
17. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
[TBL] [Abstract][Full Text] [Related]
18. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study.
Hawrelak JA; Myers SP
J Altern Complement Med; 2010 Oct; 16(10):1065-71. PubMed ID: 20954962
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Chang FY; Lu CL; Chen CY; Luo JC
J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
[TBL] [Abstract][Full Text] [Related]
20. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
Lembo A; Pimentel M; Rao SS; Schoenfeld P; Cash B; Weinstock LB; Paterson C; Bortey E; Forbes WP
Gastroenterology; 2016 Dec; 151(6):1113-1121. PubMed ID: 27528177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
